Research Article
BibTex RIS Cite

METASTATİK KÜÇÜK HÜCRE DIŞI AKCİĞER KANSERİNDE ORAL VİNORELBİNİN ÜÇÜNCÜ SERİ TEDAVİDE ETKİNLİK VE TOKSİSİTE DEĞERLENDİRMESİ: TEK MERKEZ DENEYİMİ

Year 2020, Volume: 8 Issue: 3, 429 - 435, 20.12.2020
https://doi.org/10.37696/nkmj.749751

Abstract

Öz
Amaç : Metastatik küçük hücre dışı akciğer kanserinde (KHDAK) 3. hat tedavide oral vinorelbinin etkinlik ve toksisite değerlendirmesi

Materyal ve Metot: Metastatik Küçük hücre dışı akciğer kanseri tanılı 20 hastada oral vinorelbin tedavisi tek ajan tedavisi olarak 21 günlük tedavi siklusunun 1. ve 8. günlerinde 60mg/m2 dozunda hastalık progrese oluncaya veya ilaç bırakılmasını gerektirecek toksisite gelişinceye kadar uygulandı.
Bulgular : Hastaların ortanca yaşı 64(50-78), cinsiyette Erkek-Kadın oranı 9:1 idi. Histolojik olarak, skuamöz hücreli karsinom ((%65), adenokarsinom (%30) ve tiplendirme yapılamayan (%5) olarak saptandı. 3 hastada parsiyel yanıt, 5 hastada stabil hastalık saptanmış ve 12 hastada progresyon gelişmiştir. Medyan progresyonsuz sağkalım (GA %95)=2 ay (1.3-2.6), medyan genel sağkalım (%95 GA)=8 ay (0.1-17.5) saptanmıştır. Ortalama vinorelbin 4 kür oral vinorelbin uygulanmıştır. 3/4. derece yan etki hiçbir hastada görülmedi. 1. derece anemi hastaların yarısında ve 1. derece nötropeni %20’sinde görüldü. Tamamı 1/2. derece olan hematolojik olmayan en sık yan etkiler bitkinlik %65, bulantı %35, kabızlık %25 oranındaydı.
Sonuç : Halen metastatik KHDAK’nin tedavisinde kabul edilmiş standart bir yaklaşım yok. Mevcut bulgular oral vinorelbinin tek ajan olarak uygulanmasının güvenilir ve göreceli olarak uzun dönem hastalık stabilizasyonu imkanı veren önemli bir tedavi seçeneği olabileceğini göstermektedir.

References

  • Kaynaklar : 1. National Cancer Institute. Surveillance, Epidemiology,and End Results Program. Fast stats. 2019; https://seer.cancer.gov/faststats/. Accessed January 18, 2019.
  • 2. Kose MR, ed. Health Statistics [Web resource]. Ankara, Turkey: Ministry of Health, Public Health Agency; 2015. [Available at: http://www.saglikistatistikleri.gov.tr/dosyalar/ SIY_2015.pdf (membership required); cited 10 May 2017]
  • 3. Camerini A, Banna GL, Cinieri S, Pezzuto A, Mencoboni M, Rosetti F. at al. Metronomic Oral Vinorelbine for the Treatment of Advanced Non-Small Cell Lung Cancer: A Multicenter International Retrospective Analysis. Clin Transl Oncol. 2019 Jun;21(6):790-795. doi: 10.1007/s12094-018-1989-y. Epub 2018 Nov 17.
  • 4. Barletta G, Genova C, Rijavec E, Burrafato G, Biello F, Sini C. at al.Oral Vinorelbine in the Treatment of Non-Small-Cell Lung Cancer. Expert Opin Pharmacother 2014 Aug;15(11):1585-99. doi: 10.1517/14656566.2014.934224. Epub 2014 Jun 27.
  • 5. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F. at al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95: 362-372, 2003.
  • 6. Barbolosi D, Ciccolini J, Meille C, Elharrar X, Faivre C, Lacarelle B. at al. Metronomics chemotherapy: time for computational decision support. Cancer Chemother Pharmacol 74: 647-652, 2014.
  • 7. Kolek V,Grygarkova I, Koubkova L, Skrickova J, Vecova J, Sixtova D. at al. Carboplatin With Intravenous and Subsequent Oral Administration of Vinorelbine in Resected Non-Small-Cell-Lung Cancer in Real-World Set-Up. PLoS One 2017 Jul 21;12(7):e0181803. doi: 10.1371/journal.pone.0181803. eCollection 2017.
  • 8. Schwarzenberger P, Anna Fariss, Linares L, Nedzi L, Salazar OM. Dose Escalation of Once Weekly Oral Vinorelbine Concurrent With Weekly Split Dose Hypofractionated Chest Radiation for Palliation of Advanced Non-Small Cell Lung Cancer: A Phase I/II Study. Am J Med Sci. 2011 Jun;341(6):454-9. doi: 10.1097/MAJ.0b013e3182127b3f.
  • 9. Jassem J, Ramlau R, Karnicka-Mfodkowska H, Krawczyk K., Krzakowski M, Zatlouka P. at al. A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Annuls of Oncology 12: 1375-1381.2001.
  • 10. Camerini A, Valsuani C, Mazzoni F, Siclari O, Puccetti C, Donati S. at al.Phase II trial of single-agent oral vinorelbine in elderly (≥70 years) patients with advanced non-small-cell lung cancer an poor performance status. Annals of Oncology 21: 1290–1295, 2010 doi:10.1093/annonc/mdp525
  • 11. Banna LG, Camerini A, Bronte G, Anile G, Addeo A, Rundo F. at al. Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy. Anticancer Research 38: 3689-3697 (2018) doi:10.21873/anticanres.12647
  • 12. Camerini A, Banna G.L, Cinieri S, Pezzuto A, Mencoboni M, Rosetti F. at al.Metronomic oral vinorelbine for the treatment of advanced non‑small cell lung cancer: a multicenter international retrospective analysis. Clinical and Translational Oncology (2019) 21:790–795 https://doi.org/10.1007/s12094-018-1989-y
  • 13. Bilir C, Durak S, Kızılkaya B, Hacıbekiroğlu İ, Nayır E, Engin H. Efficacy of Metronomic Vinorelbine in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Poor Performance Status. Curr Oncol. 2017 Jun;24(3):e199-e204. doi: 10.3747/co.24.3486. Epub 2017 Jun 27.
  • 14.D’Ascanio M, Aldo Pezzuto A, Fiorentino C, Sposato B, Bruno P, Grieco A. at al. Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer. Hindawi BioMed Research International Volume 2018, Article ID 6278403, 6 pages https://doi.org/10.1155/2018/6278403.
  • 15. Kontopodis E, Hatzidaki D, Varthalitis I, Kentepozidis N, Giassas S, Pantazopoulos N. at al. A Phase II Study of Metronomic Oral Vinorelbine Administered in the Second Line and Beyond in Non-Small Cell Lung Cancer (NSCLC): A Phase II Study of the Hellenic Oncology Research Group. J Chemother. 2013 Feb;25(1):49-55. doi: 10.1179/1973947812Y.0000000050.
  • 16. Pujol JL, Coffy A, Camerini A, Kotsakis A, Mencoboni M, Gusella M. at al. An Individual Patient-Data Meta-Analysis of Metronomic Oral Vinorelbine in Metastatic Non-Small Cell Lung Cancer. PLoS One. 2019 Aug 20;14(8):e0220988. doi: 10.1371/journal.pone.0220988. eCollection 2019.
Year 2020, Volume: 8 Issue: 3, 429 - 435, 20.12.2020
https://doi.org/10.37696/nkmj.749751

Abstract

References

  • Kaynaklar : 1. National Cancer Institute. Surveillance, Epidemiology,and End Results Program. Fast stats. 2019; https://seer.cancer.gov/faststats/. Accessed January 18, 2019.
  • 2. Kose MR, ed. Health Statistics [Web resource]. Ankara, Turkey: Ministry of Health, Public Health Agency; 2015. [Available at: http://www.saglikistatistikleri.gov.tr/dosyalar/ SIY_2015.pdf (membership required); cited 10 May 2017]
  • 3. Camerini A, Banna GL, Cinieri S, Pezzuto A, Mencoboni M, Rosetti F. at al. Metronomic Oral Vinorelbine for the Treatment of Advanced Non-Small Cell Lung Cancer: A Multicenter International Retrospective Analysis. Clin Transl Oncol. 2019 Jun;21(6):790-795. doi: 10.1007/s12094-018-1989-y. Epub 2018 Nov 17.
  • 4. Barletta G, Genova C, Rijavec E, Burrafato G, Biello F, Sini C. at al.Oral Vinorelbine in the Treatment of Non-Small-Cell Lung Cancer. Expert Opin Pharmacother 2014 Aug;15(11):1585-99. doi: 10.1517/14656566.2014.934224. Epub 2014 Jun 27.
  • 5. Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F. at al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95: 362-372, 2003.
  • 6. Barbolosi D, Ciccolini J, Meille C, Elharrar X, Faivre C, Lacarelle B. at al. Metronomics chemotherapy: time for computational decision support. Cancer Chemother Pharmacol 74: 647-652, 2014.
  • 7. Kolek V,Grygarkova I, Koubkova L, Skrickova J, Vecova J, Sixtova D. at al. Carboplatin With Intravenous and Subsequent Oral Administration of Vinorelbine in Resected Non-Small-Cell-Lung Cancer in Real-World Set-Up. PLoS One 2017 Jul 21;12(7):e0181803. doi: 10.1371/journal.pone.0181803. eCollection 2017.
  • 8. Schwarzenberger P, Anna Fariss, Linares L, Nedzi L, Salazar OM. Dose Escalation of Once Weekly Oral Vinorelbine Concurrent With Weekly Split Dose Hypofractionated Chest Radiation for Palliation of Advanced Non-Small Cell Lung Cancer: A Phase I/II Study. Am J Med Sci. 2011 Jun;341(6):454-9. doi: 10.1097/MAJ.0b013e3182127b3f.
  • 9. Jassem J, Ramlau R, Karnicka-Mfodkowska H, Krawczyk K., Krzakowski M, Zatlouka P. at al. A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients. Annuls of Oncology 12: 1375-1381.2001.
  • 10. Camerini A, Valsuani C, Mazzoni F, Siclari O, Puccetti C, Donati S. at al.Phase II trial of single-agent oral vinorelbine in elderly (≥70 years) patients with advanced non-small-cell lung cancer an poor performance status. Annals of Oncology 21: 1290–1295, 2010 doi:10.1093/annonc/mdp525
  • 11. Banna LG, Camerini A, Bronte G, Anile G, Addeo A, Rundo F. at al. Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy. Anticancer Research 38: 3689-3697 (2018) doi:10.21873/anticanres.12647
  • 12. Camerini A, Banna G.L, Cinieri S, Pezzuto A, Mencoboni M, Rosetti F. at al.Metronomic oral vinorelbine for the treatment of advanced non‑small cell lung cancer: a multicenter international retrospective analysis. Clinical and Translational Oncology (2019) 21:790–795 https://doi.org/10.1007/s12094-018-1989-y
  • 13. Bilir C, Durak S, Kızılkaya B, Hacıbekiroğlu İ, Nayır E, Engin H. Efficacy of Metronomic Vinorelbine in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Poor Performance Status. Curr Oncol. 2017 Jun;24(3):e199-e204. doi: 10.3747/co.24.3486. Epub 2017 Jun 27.
  • 14.D’Ascanio M, Aldo Pezzuto A, Fiorentino C, Sposato B, Bruno P, Grieco A. at al. Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer. Hindawi BioMed Research International Volume 2018, Article ID 6278403, 6 pages https://doi.org/10.1155/2018/6278403.
  • 15. Kontopodis E, Hatzidaki D, Varthalitis I, Kentepozidis N, Giassas S, Pantazopoulos N. at al. A Phase II Study of Metronomic Oral Vinorelbine Administered in the Second Line and Beyond in Non-Small Cell Lung Cancer (NSCLC): A Phase II Study of the Hellenic Oncology Research Group. J Chemother. 2013 Feb;25(1):49-55. doi: 10.1179/1973947812Y.0000000050.
  • 16. Pujol JL, Coffy A, Camerini A, Kotsakis A, Mencoboni M, Gusella M. at al. An Individual Patient-Data Meta-Analysis of Metronomic Oral Vinorelbine in Metastatic Non-Small Cell Lung Cancer. PLoS One. 2019 Aug 20;14(8):e0220988. doi: 10.1371/journal.pone.0220988. eCollection 2019.
There are 16 citations in total.

Details

Primary Language Turkish
Subjects Clinical Sciences
Journal Section Orginal Article
Authors

Lokman Koral 0000-0003-4646-4591

Publication Date December 20, 2020
Published in Issue Year 2020 Volume: 8 Issue: 3

Cite

APA Koral, L. (2020). METASTATİK KÜÇÜK HÜCRE DIŞI AKCİĞER KANSERİNDE ORAL VİNORELBİNİN ÜÇÜNCÜ SERİ TEDAVİDE ETKİNLİK VE TOKSİSİTE DEĞERLENDİRMESİ: TEK MERKEZ DENEYİMİ. Namık Kemal Tıp Dergisi, 8(3), 429-435. https://doi.org/10.37696/nkmj.749751
AMA Koral L. METASTATİK KÜÇÜK HÜCRE DIŞI AKCİĞER KANSERİNDE ORAL VİNORELBİNİN ÜÇÜNCÜ SERİ TEDAVİDE ETKİNLİK VE TOKSİSİTE DEĞERLENDİRMESİ: TEK MERKEZ DENEYİMİ. NKMJ. December 2020;8(3):429-435. doi:10.37696/nkmj.749751
Chicago Koral, Lokman. “METASTATİK KÜÇÜK HÜCRE DIŞI AKCİĞER KANSERİNDE ORAL VİNORELBİNİN ÜÇÜNCÜ SERİ TEDAVİDE ETKİNLİK VE TOKSİSİTE DEĞERLENDİRMESİ: TEK MERKEZ DENEYİMİ”. Namık Kemal Tıp Dergisi 8, no. 3 (December 2020): 429-35. https://doi.org/10.37696/nkmj.749751.
EndNote Koral L (December 1, 2020) METASTATİK KÜÇÜK HÜCRE DIŞI AKCİĞER KANSERİNDE ORAL VİNORELBİNİN ÜÇÜNCÜ SERİ TEDAVİDE ETKİNLİK VE TOKSİSİTE DEĞERLENDİRMESİ: TEK MERKEZ DENEYİMİ. Namık Kemal Tıp Dergisi 8 3 429–435.
IEEE L. Koral, “METASTATİK KÜÇÜK HÜCRE DIŞI AKCİĞER KANSERİNDE ORAL VİNORELBİNİN ÜÇÜNCÜ SERİ TEDAVİDE ETKİNLİK VE TOKSİSİTE DEĞERLENDİRMESİ: TEK MERKEZ DENEYİMİ”, NKMJ, vol. 8, no. 3, pp. 429–435, 2020, doi: 10.37696/nkmj.749751.
ISNAD Koral, Lokman. “METASTATİK KÜÇÜK HÜCRE DIŞI AKCİĞER KANSERİNDE ORAL VİNORELBİNİN ÜÇÜNCÜ SERİ TEDAVİDE ETKİNLİK VE TOKSİSİTE DEĞERLENDİRMESİ: TEK MERKEZ DENEYİMİ”. Namık Kemal Tıp Dergisi 8/3 (December 2020), 429-435. https://doi.org/10.37696/nkmj.749751.
JAMA Koral L. METASTATİK KÜÇÜK HÜCRE DIŞI AKCİĞER KANSERİNDE ORAL VİNORELBİNİN ÜÇÜNCÜ SERİ TEDAVİDE ETKİNLİK VE TOKSİSİTE DEĞERLENDİRMESİ: TEK MERKEZ DENEYİMİ. NKMJ. 2020;8:429–435.
MLA Koral, Lokman. “METASTATİK KÜÇÜK HÜCRE DIŞI AKCİĞER KANSERİNDE ORAL VİNORELBİNİN ÜÇÜNCÜ SERİ TEDAVİDE ETKİNLİK VE TOKSİSİTE DEĞERLENDİRMESİ: TEK MERKEZ DENEYİMİ”. Namık Kemal Tıp Dergisi, vol. 8, no. 3, 2020, pp. 429-35, doi:10.37696/nkmj.749751.
Vancouver Koral L. METASTATİK KÜÇÜK HÜCRE DIŞI AKCİĞER KANSERİNDE ORAL VİNORELBİNİN ÜÇÜNCÜ SERİ TEDAVİDE ETKİNLİK VE TOKSİSİTE DEĞERLENDİRMESİ: TEK MERKEZ DENEYİMİ. NKMJ. 2020;8(3):429-35.